In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Philips Medical Systems

This article was originally published in The Gray Sheet

Executive Summary

Receives FDA clearance to market its CVI-Q (color velocity imaging-quantification) technique, which the company claims is the first color flow ultrasound method "for directly quantifying the velocity and volume of blood flow in vessels." Using Philips' proprietary technology of "time domain signal processing," CVI-Q can provide measurements that improve physicians' precision in "diagnosing and determining the best treatment for vascular disorders," Philips says
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT001713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel